Navigation Links
Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
Date:3/14/2017

SAN DIEGO, March 14, 2017 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced the appointment of Alexey Vinogradov, Ph.D., to its board of directors. Dr. Vinogradov currently serves as Head of Pharmstandard Ventures, a corporate venture fund of Pharmstandard Group, until recently known as Inbio Ventures, where he served as a Managing Partner and CEO. Dr. Vinogradov replaces Dr. Andrei Petrov as a director of the company.

"We are excited to have Alexey join our board during this exciting time of Avelas' corporate development," said Carmine Stengone, president and CEO of Avelas Biosciences. "Alexey has considerable experience in research and development, operations and business development, and I'm confident he will contribute meaningfully to our future success."

Dr. Vinogradov has over 15 years of experience at different positions in the biotech industry. He has served as a board member at Argos Therapeutics, as a board observer at Protagonist Therapeutics and Aquinox, and currently serves as a board observer at Allena Pharmaceuticals. Prior to joining Inbio Ventures in 2012, as co-founding partner and CBO, Dr. Vinogradov was involved in portfolio building at Bioprocess Capital Partners. He also led the fundraising and served in the executive management of Promogene, Tartis-Oncology and Everon. In addition, Dr. Vinogradov was involved in a range of business development activities at Bioprocess Group.

Dr. Vinogradov held a postdoctoral position at the Laboratory of Biomolecular Sciences, Wageningen University, Netherlands. He obtained his Ph.D. degree in Biochemistry and MS degree in Chemistry from Moscow State University.

About Avelas Biosciences

Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. The initiation of a Phase 2 clinical trial for AVB-620 in breast cancer is expected in the first half of 2017. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avelas-biosciences-appoints-alexey-vinogradov-phd-to-board-of-directors-300423042.html


'/>"/>
SOURCE Avelas Biosciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Avelas Biosciences to Present at 28th Annual Roth Conference
2. Representative Scott Peters Visits Avelas Biosciences
3. Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients
4. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
5. Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
6. DuPont Industrial Biosciences Leader Presents Major Advances in Biomaterials at 2017 Advanced Bioeconomy Leadership Conference
7. Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation
8. ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
9. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
10. Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
11. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... November 12, 2019 , ... ... software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies , ... Genedata Biologics® to streamline their R&D operations related to the ...
(Date:11/9/2019)... ... November 08, 2019 , ... PathAI, a ... today announced the results of analyses examining the severity of nonalcoholic steatohepatitis ... selonsertib studies (STELLAR). Strong correlations were demonstrated between AI-powered and manual pathologist ...
(Date:11/5/2019)... ... 2019 , ... Focal Healthcare , an innovator of ... Bx 2.0 prostate fusion biopsy solution. By combining information from multiparametric MRI (mpMRI) ... urologists across Europe the ability to perform targeted transrectal and transperineal prostate biopsies. ...
(Date:11/2/2019)... ... October 31, 2019 , ... drug360 ... intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language processing and ... to quickly uncover relationships between genes, diseases, variants, phenotypes, and other biomedical entities. ...
Breaking Biology Technology:
(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current hot topics ... Access to all webinars is free, so be sure to register today to save ... http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , November 14 ...
(Date:10/30/2019)... ... October 30, 2019 , ... Analogous to ... encoded by the ordering of monomer residues into specific sequences along their ... attachment to the backbone amide-nitrogen atoms. They are resistant to protease degradation ...
(Date:10/26/2019)... ... October 23, 2019 , ... ... Christina Hughes , to its executive leadership team. , As a market leader ... allow growth-stage biotech and pharma companies to reduce timelines and improve quality with ...
Breaking Biology News(10 mins):